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Process for the preparation of crystalline form of 4-(4-{3-[4-chloro-3(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide
A process for the preparation of crystalline form of 4-(4-{3-[4-chloro-3(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide

compound

of

formula-I, which is represented by the following structural formula:

Formula-I
Sorafenib,

chemically

known

as

4-(4-{3-[4-chloro-3-(trifluoromethyl)

phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide compound of formula-I and is
approved as Sorafenib tosylate by USA & Europe under the brand name NEXAVAR ® for the
treatment of advanced renal cell carcinoma (primary kidney cancer) and advanced
hepatocellular carcinoma (primary liver cancer).
The present disclosure provides a process for the preparation of crystalline form of
sorafenib freebase. Dimethylsulfoxide is used to dissolve sorafenib freebase, solidified the
freebase by using aqueous methanol to obtain desired crystalline form of Sorafenib freebase.
The compound of formula-I used in the present invention is prepared by any of the
processes known in prior art.
The following example specifies the conditions of the process for the preparation of
crystalline sorafenib freebase.
Example: Preparation of crystalline form of Sorafenib freebase.
Sorafenib freebase (500 g) was added to the dimethylsulfoxide (900 ml) at 25-30°C
and stirred for 10 minutes at the same temperature. Heated the reaction mixture to 50-55°C
and stirred for 15 minutes at the same temperature. Filtered the reaction mixture at 50-55°C.
aqueous methanol (water 1125 ml and methanol 8750 ml) was added to the filterate at 2530°C. Cooled the raction mixture to 10-15°C and stirred for 60 minutes at the same
temperature. Filtered the precipitated solid and washed with aqueous methanol (water 90 ml
and methanol 810 ml). obtained wet compound was added to dimethylsulfoxide (100 ml) at
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25-30°C and stirred for 10 minutes at the same temperature. aqueous methanol (water 900 ml
and methanol 8100 ml) was added to the reaction mixture at 25-30°C. Cooled the reaction
mixture to 10-15°C and stirred for 60 minutes at the same temperature. Filtered the
precipitated solid and washed with aqueous methanol (water 90 ml and methanol 810 ml).
Dried the compound to obtain crystalline form of sorafenib freebase.
Yield: 80.2 %
M.R: 205-208°C
HPLC purity: 99.63%
PXRD: Figure-I

Figure-I
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